Correlation Between Novo Nordisk and Kalvista Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Novo Nordisk and Kalvista Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Novo Nordisk and Kalvista Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Novo Nordisk AS and Kalvista Pharmaceuticals, you can compare the effects of market volatilities on Novo Nordisk and Kalvista Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Novo Nordisk with a short position of Kalvista Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Novo Nordisk and Kalvista Pharmaceuticals.
Diversification Opportunities for Novo Nordisk and Kalvista Pharmaceuticals
0.45 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Novo and Kalvista is 0.45. Overlapping area represents the amount of risk that can be diversified away by holding Novo Nordisk AS and Kalvista Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Kalvista Pharmaceuticals and Novo Nordisk is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Novo Nordisk AS are associated (or correlated) with Kalvista Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Kalvista Pharmaceuticals has no effect on the direction of Novo Nordisk i.e., Novo Nordisk and Kalvista Pharmaceuticals go up and down completely randomly.
Pair Corralation between Novo Nordisk and Kalvista Pharmaceuticals
Assuming the 90 days horizon Novo Nordisk AS is expected to under-perform the Kalvista Pharmaceuticals. But the pink sheet apears to be less risky and, when comparing its historical volatility, Novo Nordisk AS is 1.55 times less risky than Kalvista Pharmaceuticals. The pink sheet trades about -0.03 of its potential returns per unit of risk. The Kalvista Pharmaceuticals is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest 1,027 in Kalvista Pharmaceuticals on September 1, 2024 and sell it today you would lose (21.00) from holding Kalvista Pharmaceuticals or give up 2.04% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Novo Nordisk AS vs. Kalvista Pharmaceuticals
Performance |
| Timeline |
| Novo Nordisk AS |
| Kalvista Pharmaceuticals |
Novo Nordisk and Kalvista Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Novo Nordisk and Kalvista Pharmaceuticals
The main advantage of trading using opposite Novo Nordisk and Kalvista Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Novo Nordisk position performs unexpectedly, Kalvista Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kalvista Pharmaceuticals will offset losses from the drop in Kalvista Pharmaceuticals' long position.| Novo Nordisk vs. Rigel Pharmaceuticals | Novo Nordisk vs. Geron | Novo Nordisk vs. Verastem | Novo Nordisk vs. Immutep Ltd ADR |
| Kalvista Pharmaceuticals vs. Crinetics Pharmaceuticals | Kalvista Pharmaceuticals vs. Kura Oncology | Kalvista Pharmaceuticals vs. Viridian Therapeutics | Kalvista Pharmaceuticals vs. Replimune Group |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Complementary Tools
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |